Storify from last night's #NephJC on PPI and CKD

joel topf

March 16, 2016

Hector was right out of the gate with a 131 tweet Storify of the chat.

Embed Block

Add an embed URL or code. Learn more

Tweet Feed

Thanks again, goodnight all #NephJC
about 6 hours ago
Do you like to have some #NephJC swag? Order it here https://t.co/eTUrZY27Qo
about 6 hours ago
If you haven’t, please sign up for our weekly newsletter https://t.co/5aumn8qL85 #NephJC
about 6 hours ago
That's a wrap. Thanks to all for joining me tonight and a huge thank you to @aakashshingada for his help tonight, a… https://t.co/wj1sFvsdKx
about 6 hours ago
Last few minutes left. What are your take home points? Final thoughts/comments? #NephJC
about 6 hours ago
T4D: Last few minutes left. What are your take home points? Final thoughts/comments? #NephJC
about 6 hours ago
T3I:: Do we need a trial of differing PTH targets (using calcimimetics or VDRAs and other drugs to achieve the PTH)… https://t.co/oCmk4xUuGs
about 6 hours ago
T3I: Do we need a trial of differing PTH targets (using calcimimetics or VDRAs and other drugs to achieve the PTH)?… https://t.co/kmvbpHGH1J
about 6 hours ago
T3H: Does this open the door for a trial of active vitamin D, or a VDRAs at higher levels of PTH? #NephJC
about 6 hours ago
T3G: Does this study change your practice? Do you, or will you, treat your CKD-D patients with VDRA in the setting… https://t.co/P21stFgV6A
about 6 hours ago
T3E: What does this trial truly show? VDRAs have been promoted for improving cardiovascular health, immune function… https://t.co/ZPheyc9Of3
about 6 hours ago
T3F: Rx of HD patients with normal PTH has been said to promote adynamic bone disease, subsequently increasing risk… https://t.co/9vShOeey7K
about 6 hours ago
T3D: This was not a trial of different PTH targets, it was a trial of alfacalcidol versus placebo (most of whom did… https://t.co/8G42uAWk1P
about 6 hours ago
T3C: What do you think of the trial, the results? There were some significant limitations – Underpowered Trial Unbl… https://t.co/xy3yruTGba
about 6 hours ago
T3B: The study has a signal of potential harm rather than benefit of VDRAs in patients without elevated serum intac… https://t.co/E1i8Ex1Hoa
about 6 hours ago
T3A: The trial showed that in patients without secondary hyperparathyroidism receiving maintenance hemodialysis, or… https://t.co/dGQcbKiAMn
about 6 hours ago
RT @carlo_alfieri: @NephJC honestly speaking not surprised. For 2 reasons: 1) we do not know native vitamin D status of those patient… https://t.co/s6Xrts0wMj
about 6 hours ago
T2I: Any other thoughts on results? #NephJC
about 6 hours ago
T2H: One might wonder why the biochemical parameters not change despite a drug versus no drug comparison? The answe… https://t.co/JhMdONbk2O
about 6 hours ago
T2G: What happened to calcium, PO4 and PTH during the trial? Since this was an open label a lot of changes were ma… https://t.co/nkp2gfyPwm
about 6 hours ago